Interview 31 May 2017 Poll: Academia, Biotech or Another Career? How Industry Leaders Decided Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […] May 31, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2017 Swiss Researchers get to the Genetic Bottom of Kidney Cancer Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 30 May 2017 FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […] May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira Meet the founder of three hot British biotechs developing antibody-related technologies. Despite his interest in business, he remains an academic at heart. Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first company in […] May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2017 “Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […] May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2017 UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […] May 26, 2017 - 4 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2017 Resilient Tumor Cells Drive Breast Cancer Relapse in Mice Tumor cells that survive chemotherapy and drive breast cancer relapse may provide drug targets for potential treatments to reduce the recurrence. In mice, some breast tumor cells can survive chemotherapy and drive the recurrence of tumor, found a team of researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and in Monterotondo, Italy; […] May 25, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 25 May 2017 How Biotech Will Make Us Live Longer – Let’s Talk Anti-Aging Last week, at our first Labiotech Hangout, Philip had a chat with James Peyer, a partner at Apollo Ventures, to ask a few questions about how biotech is tackling the anti-aging space. For a long time, the anti-aging field has not seen much innovation, both due to a lack of scientific know-how as well as a lack of […] May 25, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 25 May 2017 Cross-Innovation in Healthcare – Discussing Trends and Challenges At Bionnale in Berlin last week, Joachim moderated a panel discussion on the topic of cross-innovation in biotech. Here’s our recap. Cross-innovation is key to areas like biotech and healthcare, bringing together different industries to generate new solutions. Although the companies represented at the recent cross-innovation panel were coming from very distinct fields, the three panelists had a […] May 25, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […] May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Seed Funding for a German Cell Therapy to Prevent Transplant Rejection TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […] May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email